COVID 19 Impact Analysis: DPT Vaccine Market: Latest Trends, Growth, And Profitability

DPT Vaccine Market – Overview

Global DPT Vaccine Market Size is growing exponentially owing to rising prevalence of chronic disease and increasing usage of combination vaccine and therapy are the major factor driving the DPT vaccine Market. Globally the market for DPT vaccine market is expected to grow at the rate of about 7.3% CAGR from 2016 to 2027.

There is an increase in demand of diphtheria tetanus and pertussis vaccine across the globe and rising awareness regarding prevention of diphtheria, tetanus, and pertussis is major factors which are responsible for the growth of this market. The market is expected to show large opportunities in the coming future with the advancement of technology in developing countries and new products with increased accuracy.

Diverging product markets can be seen in preferences for traditional vaccines such as DTP. According to WHO, developed countries prefer to purchase a component of the DPT vaccines such as procure acellular pertussis (DTaP), while most developing countries purchase vaccines with whole cell pertussis (DTwP) components.

However, some of the challenges which the market is expected to face includes competition from new entrants or big pharmaceutical giants entering the business or market and the continuous advancements in the product. Furthermore there are some hindering factors which are restricting the market growth such as side effects and complications during inhalation, high prices of devices, and lack of accuracy etc.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @

Global DPT vaccine Market – Regional Analysis

Globally, DPT Vaccine market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa.  North America is the largest market for diphtheria tetanus and pertussis vaccine (DPT) vaccine.

The North American market for DPT Vaccine is expected to grow steadily over the forecasted period. This is due to the presence of high concentration of major market players in North America and its emphasis on vaccination against DPT. North American market consists of countries like the U.S., Canada and Mexico. Death rate sue communicable disease is seen to be growing, thus highlighting the importance of immunization. For instance, In March 2015 U.S FDA approved the use of Quadracel for immunization of children from 4 to 6 years of age. This was a great achievement for Sanofi helping it to maintain its leading position in the market.

Europe is the second-largest market for DPT Vaccine which is expected to grow at an overwhelming CAGR during the forecast period. This is due to increasing research and development activities by pharmaceutical companies and research institutes. The market is growing continuously in Europe as the key market players invested huge financial resources on research and development activities for the production of effective vaccines.  Increasing awareness about immunization of children against Diphtheria, tetanus and pertussis also drive this market in Europe.

Moreover, Asia Pacific is expected to be the fastest growing market for DPT Vaccine market. India is expected to be the emerging and fastest growing market. Presence of large patient pool drive this market in Asia-pacific. This region is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. Governments in developing countries of Asia-Pacific have undertaken various vaccinations programs. National Health Mission in India provide vaccination against diphtheria, pertussis, tetanus and polio.

The market shows steady growth in Middle East and Africa. In Middle East and Africa the demand for DPT vaccine is less than other regions across the globe.

Global DPT vaccine Market – Company Analysis

Merck: Merck provides a wide range of vaccines which includes BCG USP, Pneumonix, Varivax, Pedvax HIB, Recombivax HB and others.

Sanofi: Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, consumer healthcare, established prescription products and generics. Diphtheria and Tetanus Toxoids and acellular Pertussis Vaccine called Daptacel is the product offered by Sanofi which is the major market player.

Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), Wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India), Serum Institute of India Pvt. Ltd. (India), Lanzhou Institute of Biological Products (China) and others are some of the prominent players at the forefront of competition in the Global DPT vaccine Market and are profiled in MRFR Analysis. 

Obtain Premium Research Report Details, Considering the impact of COVID-19 @

DPT Vaccine Industry News

The Indian Industries Association (IIA) has decided to help the UP government in India to implement the one district one product (ODOP) scheme in 45 districts where the industry lobby group has a direct presence. 23 JUL 2018

The Department of Health-Center for Health Development (DOH-CHD) has started a vaccination program in Western Visayas, Philippines. It is counting on the support of local government units (LGUs) for the success of this program. In this program, the basic vaccination includes one dose of the BCG vaccine, three doses of the DPT vaccine, one dose of the MMR vaccine, and three doses of polio vaccine. 11 DEC 2018